CN103169079A - Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof - Google Patents
Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof Download PDFInfo
- Publication number
- CN103169079A CN103169079A CN201310068468XA CN201310068468A CN103169079A CN 103169079 A CN103169079 A CN 103169079A CN 201310068468X A CN201310068468X A CN 201310068468XA CN 201310068468 A CN201310068468 A CN 201310068468A CN 103169079 A CN103169079 A CN 103169079A
- Authority
- CN
- China
- Prior art keywords
- mouse
- immunity
- ginseng
- antifatigue
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 title abstract description 10
- 235000013305 food Nutrition 0.000 title abstract 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 241001165494 Rhodiola Species 0.000 claims abstract description 12
- 235000018905 epimedium Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 230000036039 immunity Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 244000131316 Panax pseudoginseng Species 0.000 claims description 19
- 235000013402 health food Nutrition 0.000 claims description 18
- 241001016310 Epimedium grandiflorum Species 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 claims description 6
- 235000011201 Ginkgo Nutrition 0.000 claims description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 6
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 6
- 240000006079 Schisandra chinensis Species 0.000 claims description 6
- 241001533104 Tribulus terrestris Species 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 240000005373 Panax quinquefolius Species 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims 2
- 230000008859 change Effects 0.000 abstract description 4
- 241000208340 Araliaceae Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 240000000759 Lepidium meyenii Species 0.000 abstract 1
- 235000000421 Lepidium meyenii Nutrition 0.000 abstract 1
- 235000012902 lepidium meyenii Nutrition 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 67
- 230000037396 body weight Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- 238000003304 gavage Methods 0.000 description 22
- 230000009182 swimming Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 230000000242 pagocytic effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 229920002527 Glycogen Polymers 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 229940096919 glycogen Drugs 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000218628 Ginkgo Species 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 206010013183 Dislocation of vertebra Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000013103 analytical ultracentrifugation Methods 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a health-care food with anti-fatigue and immunity-enhancing effects. The food comprises the components of, by weight, 10-50% of ginseng, 10-50% of epimedium, 10-30% of kirilow rhodiola root and rhizome, and 5-15% of maca. The invention also discloses a preparation method of the health-care food. According to the invention, pure natural traditional Chinese medicines are adopted as raw materials. The anti-fatigue and immunity-enhancing effects are achieved, and no side effect is caused. The food is suitable for people of various ages. Also, the preparation method is simple. Raw material property change is prevented, and the food can be preserved for a long time.
Description
Technical field
The invention belongs to the medicines and health protection field, be specifically related to a kind ofly have antifatigue, strengthen health food of immunity and preparation method thereof.
Background technology
Tired as a kind of physiological phenomenon, is a kind of mechanism of protectiveness to the people, be that health sends the signal that have a rest to us, if to it no matter ignore, health will suffer damage.The develop rapidly of science and technology makes the household electrical appliances such as mobile phone, TV, computer, fluorescent lamp, micro-wave oven, electromagnetic oven, air-conditioning, hair-dryer, dust catcher become the necessary articles for use of every household, these household electrical appliances are when bringing convenience to people, also make people be in the encirclement of electromagnetic radiation, be in for a long time in the environment of electromagnetic radiation, can make the people have in various degree feel headache, dizzy, feel sick, the fatigue symptom such as tinnitus, eyes are dry and astringent.
Immunity is the defense mechanism of human body self, be human body identification and any foreign matter (virus, bacterium etc.) of eliminating external intrusion, process the ability of self cell and identification and processing vivo mutations cell and the virus infected cell of old and feeble, damage, death, sex change.Immune dysfunction or when low can reduce body to anti-infectious ability, reduces identification and removes the histocyte ability of self aging, reduces and kills and wounds and remove abnormal sudden change cell ability in vivo, causes the decline of human body premunition and vis medicatrix naturae.And modern society, the quickening of rhythm of life, the increase of competitive pressure, every day, the working and learning meeting of anxiety made body be in the overdraw state, as can not get having a rest timely and adjusting, and accumulated over a long period, will the Immunosuppression function; Simultaneously, nervous working and learning allow the more people instant fast food of having to, and cause the unbalance of endotrophic element, if body is in this state for a long time, immunity of organisms are descended, and finally cause the sub-health state of body.
Therefore, take in fatigue resistant health food and strengthen the immunity health food and be sought after, certainly, not only had antifatigue effect but also the health food that strengthens immunity had been arranged more practical if can provide a kind of.
Summary of the invention
Goal of the invention: the object of the invention is to for the deficiencies in the prior art, a kind of health food that has antifatigue, strengthens immunity is provided.
Another object of the present invention is to provide the preparation method of above-mentioned health food.
Technical scheme: in order to reach the foregoing invention purpose, the present invention specifically is achieved like this: a kind of health food that has antifatigue, strengthens immunity comprises the component of following percentage by weight: 10～50% ginseng, 10～50% barrenwort, 10～30% rhodiola root and 5～15% agate coffee.
Preferably, the component by following percentage by weight forms: 33% ginseng, 33% barrenwort, 22% rhodiola root and 12% agate coffee.
Wherein, component of the present invention can also comprise that percentage by weight is 5～60% ginkgo, 5～50% pseudo-ginseng, 5～50% puncture vine and 5～30% the fruit of Chinese magnoliavine.Preferably, the component by following percentage by weight forms: 20% ginseng, 20% barrenwort, 10% rhodiola root, 10% agate coffee, 20% ginkgo, 10% pseudo-ginseng, 5% puncture vine and 5% the fruit of Chinese magnoliavine.
Wherein, in above-mentioned recipe ingredient, ginseng can be replaced by American Ginseng.
Prepare above-mentioned arbitrary method that has antifatigue, strengthens the health food of immunity, comprise the following steps: measure each raw material by formula, sieve respectively, mixed 15～20 minutes, make capsule.
Wherein, select≤100 mesh sieves.
Beneficial effect: it is raw material that the present invention adopts natural traditional Chinese medicine, when reaching antifatigue, strengthening immunity, can not have side effects, and is fit to all age group crowd; Simultaneously, preparation method of the present invention is simple, can not cause the variation of each feedstock property, can long preservation.
The specific embodiment
Embodiment 1:
Get percentage by weight and be 10% ginseng, 10% barrenwort, 10% rhodiola root, 5% agate coffee, 30% ginkgo, 15% pseudo-ginseng, 10% puncture vine and 10% the fruit of Chinese magnoliavine and pulverize, cross 100 mesh sieves, mixed 15 minutes, pour into capsule.
Embodiment 2:
The pueraria root powder of getting percentage by weight and be 20% ginseng, 35% barrenwort, 30% rhodiola root and 15% is broken, crosses 80 mesh sieves, mixes 15 minutes, pours into capsule.
Embodiment 3:
The pueraria root powder of getting percentage by weight and be 30% ginseng, 50% barrenwort, 10% rhodiola root and 10% is broken, crosses 100 mesh sieves, mixes 20 minutes, pours into capsule.
Embodiment 4:
Get percentage by weight and be 40% ginseng, 10% barrenwort, 10% rhodiola root, 5% agate coffee, 15% ginkgo, 5% pseudo-ginseng, 10% puncture vine and 5% the fruit of Chinese magnoliavine and pulverize, cross 80 mesh sieves, mixed 20 minutes, pour into capsule.
Embodiment 5:
The pueraria root powder of getting percentage by weight and be 50% ginseng, 20% barrenwort, 20% rhodiola root and 10% is broken, crosses 80 mesh sieves, mixes 20 minutes, pours into capsule.
Embodiment 6:
The research of anti-fatigue effect of the present invention
1. material
1.1 sample: provided by the Wuxi City health bio tech ltd of being bestowed by heaven, the human body recommended amounts was 0.45 * 4/ people/day (30mg/kg.bw).
1.2 animal used as test and raising
SPF level male ICR mouse, body weight 19～22g.
1.3 key instrument
SBA-bio-sensing analyzer, Olympus AU400 type automatic biochemistry analyzer, VIS-7200 visible spectrophotometer, refiner, centrifuge, electronic balance.
2. experimental technique
2.1 dosage is selected
Animal used as test is divided into blank group and 3 test group of the present invention at random.Tested material dosage is respectively 300mg/kg.bw, 600mg/kg.bw, 900mg/kg.bw(and is equivalent to respectively 10,20 and 30 times of human body recommended intake).Gavage liquid preparation: take 0.6g, 1.2g and 1.8g sample of the present invention, be dissolved in respectively in 40ml distilled water, press the 20mg/kg.bw gavage.The blank treated animal is with the distilled water gavage, and each experimental group animal is with the distilled water solution gavage of corresponding dosage, and once a day, gavage was tested after 30 days continuously
2.2 experimental procedure
2.2.1 swimming with a load attached to the body experiment: after last gives tested material 30min, the mouse of afterbody load 5% body weight sheet lead is placed in the swimming trunk went swimming.Many and the 30cm of the depth of water in case, 25 ± 1 ℃ of water temperatures record mouse and begin to Post-dead duration from swimming.
2.2.2 blood Plasma lactate: after last gave tested material 30min, it was not swimming with a load attached to the body 10min in the water of 30 ℃ that animal is put temperature, and before swimming, after swimming immediately, rest 20min respectively adopts eyeball blood 20 μ L mensuration lactic acid contents after swimming.And calculate blood lactic acid TG-AUC by following formula, with blood lactic acid situation of change after the judgement motion.Blood lactic acid TG-AUC=5 * (rest 20min blood Lactate after 0min blood Lactate+2 after blood Lactate before swimming+3 * swimming * swimming)
2.2.3 serum urea nitrogen determination: after last gives tested material 30min, it is not swimming with a load attached to the body 90min in the water of 30 ℃ that mouse is put temperature, adopt eyeball blood 0.5mL after rest 60min, get serum after blood clotting and measure the serum urea nitrogen content with Olympus AU400 type automatic biochemistry analyzer.
2.2.4 hepatic glycogen is measured: give tested material 30min in last and put to death animal, get liver and blot with filter paper after the physiological saline rinsing, take rapidly liver 100mg, measure hepatic glycogen content (anthrone method).
3. experimental data is added up
Experimental data is carried out variance analysis with the PEMSforWindows3.0 statistical package; The heterogeneity of variance data are carried out suitable variable conversion; If do not reach yet the neat person of variance after the variable conversion, add up with rank test.
4 results
4.1 the impact of the present invention on Mouse Weight
The impact (swimming with a load attached to the body experiment) of table 1 the present invention on Mouse Weight
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| ? | mg/kg.BW | Only | g | g | g |
| The blank group | 0 | 10 | 20.3±1.0 | 34.4±3.2 | 39.1±4.1 |
| Low dose group | 300 | 10 | 20.3±1.0 | 34.5±3.6 | 38.7±4.2 |
| Middle dosage group | 600 | 10 | 20.3±1.0 | 33.7±3.3 | 37.8±4.2 |
| High dose group | 900 | 10 | 20.3±1.0 | 33.8±1.7 | 36.9±2.3 |
The impact (blood Plasma lactate) of table 2 the present invention on Mouse Weight
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| ? | mg/kg.BW | Only | g | g | g |
| The blank group | 0 | 10 | 20.3±1.0 | 34.7±3.2 | 38.7±5.3 |
| Low dose group | 300 | 10 | 20.3±1.0 | 35.1±2.3 | 40.2±2.4 |
| Middle dosage group | 600 | 10 | 20.3±1.0 | 36.2±2.2 | 40.1±3.5 |
| High dose group | 900 | 10 | 20.3±1.0 | 34.6±3.2 | 38.7±3.3 |
The impact (determination of urea nitrogen) of table 3 the present invention on Mouse Weight
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| ? | mg/kg.BW | Only | g | g | g |
| The blank group | 0 | 10 | 20.3±1.0 | 35.3±2.3 | 39.3±3.4 |
| Low dose group | 300 | 10 | 20.3±1.0 | 33.7±2.2 | 36.9±3.1 |
| Middle dosage group | 600 | 10 | 20.3±1.0 | 34.3±2.5 | 39.2±2.5 |
| High dose group | 900 | 10 | 20.3±1.0 | 34.2±3.4 | 37.7±4.4 |
The impact (hepatic glycogen mensuration) of table 4 the present invention on Mouse Weight
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| ? | mg/kg.BW | Only | g | g | g |
| The blank group | 0 | 10 | 20.3±1.0 | 34.2±2.2 | 38.3±4.1 |
| Low dose group | 300 | 10 | 20.3±1.0 | 34.6±1.6 | 37.8±2.5 |
| Middle dosage group | 600 | 10 | 20.3±1.0 | 35.3±2.3 | 38.2±3.4 |
| High dose group | 900 | 10 | 20.3±1.0 | 33.5±2.2 | 37.6±2.2 |
Body weight there was no significant difference when by table 1-4 as seen, between three dosage combination blank groups of the present invention, the initial body weight of mouse, experiment body weight in mid-term and experiment finish (P〉0.05).Show the present invention on Mouse Weight without impact.4.2 the impact of the present invention on the mice burden swimming time
The impact of table 5 the present invention on the mice burden swimming time
4.3 the impact of the present invention on the Mouse Blood lactic acid content
The impact of table 6 the present invention on the Mouse Blood lactic acid content
By as seen from Table 6, each dosage group rear three time point blood lactic acid TG-AUCs of swimming of the present invention and blank group there was no significant difference (P〉0.05).
4.4 the impact of the present invention on the mice serum urea nitrogen content
The impact of table 7 the present invention on the mice serum urea nitrogen content
By as seen from Table 7,3 dosage group serum urea nitrogen contents of the present invention are significantly lower than blank group (P＜0.05, P＜0.01).
4.5 the impact of the present invention on the Mouse Liver glycogen content
The impact of table 8 the present invention on the Mouse Liver glycogen content
By as seen from Table 8, low dose group hepatic glycogen content of the present invention is significantly higher than blank group (P＜0.05).
5. sum up
The present invention significantly is longer than blank group (P＜0.05) the middle and high dosage group mice burden swimming time; Basic, normal, high three dosage group serum urea nitrogen contents are significantly lower than blank group (P＜0.05, P＜0.01); The low dose group hepatic glycogen content is significantly higher than blank group (P＜0.05).Can judge according to " health food check and assessment technique standard " version in 2003, the present invention has the function of antifatigue.
Embodiment 7:
The present invention strengthens the immunity function experimental study
1. material
1.1 sample: provided by the Wuxi City health bio tech ltd of being bestowed by heaven.
1.2 animal used as test
160 of Kunming mouses, entirely female, body weight 18-22g.
2. experimental technique
2.1 dosage is selected
Tested material is established 400mg/kg.BW, 800mg/kg.BW, three dosage groups of 1200mg/kg.BW (be equivalent to respectively human body recommended intake 10 times, 20 times, 30 times), take respectively 10.00g, 20.00g, 30.00g tested material adding distil water to the 250ml mixing, stored refrigerated, be finished again and join, separately establish the edible vegetable oil negative control group, every group of 40 animals.Be divided into immune one group, two groups, three groups, four groups, wherein engulf the chicken red blood cell experiment for Turnover of Mouse Peritoneal Macrophages for one group; Two groups are used for NK cytoactive detection and lymphocyte transformation experiment; Three groups are used for antibody-producting cell experiment, serum hemolysin mensuration and delayed allergy; Four groups are used for mouse carbon and clean up experiment.Mouse is pressed per os gavage of 10mg/kg.BW body weight, gives continuously 30 days, claims weekly body weight one time, adjusts the gavage volume.
2.2 experimental procedure
2.2.1 mouse carbon clearance test: gavage is after 30 days continuously, in the india ink of mouse tail vein injection with 4 times of normal saline dilutions, timing immediately after pressing 0.1ml/10g prepared Chinese ink and injecting is after injecting prepared Chinese ink the 2nd, 10min gets blood 20 μ l from the angular vein clump respectively, is added to 2mlNa
2CO
3In solution, with Na
2CO
3Solution is made blank, measures OD value at the 600nm place with 723 spectrophotometers.Put to death mouse after getting blood, get liver, spleen is weighed, calculate phagocytic index.
2.2.2 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment (half intracorporal method): gavage is after 30 days continuously, the chicken erythrocyte suspension 1ml of every mouse peritoneal injection 20%, after 30 minutes, the cervical vertebra dislocation is put to death, be fixed on the mouse plate, abdominal skin is cut off in the center, through Intraperitoneal injection physiological saline 2ml, rotated the mouse plate 1 minute, sucking-off abdominal cavity washing lotion 1ml, mean droplet is on 2 slides, put 37 ℃, wet box 30 minutes, and took out in the physiological saline rinsing, dry, fixing, 4%GiemsaPBS dyeing 3 minutes, the distilled water rinsing is dried, microscopy.Calculate phagocytic percentage and phagocytic index.
2.2.3 delayed allergy (DTH) (the sufficient sole of the foot thickens method): gavage is after 30 days, to the mouse peritoneal injection 2% every mouse of hematocrit SRBC(0.2ml/) sensitization is after 4 days, measure left back sufficient sole of the foot thickness, and then measuring point hypodermic injection 20%(v/v) the every mouse of SRBC(20 μ l/), 24h measures left back sufficient sole of the foot thickness after injection, same position is measured three times, averages, and represents the degree of DTH with sufficient sole of the foot thickness difference (swelling degree of the paw) before and after attacking.
2.2.4ConA the mouse lymphocyte conversion test (mtt assay) of inducing: at first carry out the preparation of splenocyte suspension.Cell concentration is adjusted into 3 * 10
6Then individual/ml divides cell suspension two holes to add in 24 well culture plates, every hole 1ml, and a hole adds 75 μ lConA liquid, and another hole compares, and puts 5%CO
237 ℃ of cultivation 72h of incubator.Cultivate and finish front 4h, every hole sucks gently supernatant 0.7ml and adds 0.7ml not contain the RPMI1640 nutrient solution of calf serum, add simultaneously MTT (5mg/ml) 50 μ l/ hole continuation to cultivate 4h, after cultivating end, every hole adds 1ml acid isopropyl alcohol, purple crystal is dissolved fully, then every hole liquid is moved in cuvette, with 723 spectrophotometers in 570nm wavelength place's colorimetric estimation OD value.
2.2.5 antibody-producting cell detects (Jernr improves slide method): gavage is after 30 days continuously, every mouse peritoneal injection 2% hematocrit SRBC0.2ml, mouse cervical vertebra dislocation with immunity after 5 days half is put to death, and takes out spleen and is placed in the plate that fills Hank ' s liquid, makes splenocyte suspension.Agarose is made into 1% aqueous solution, and 30min is boiled in water-bath, mix with the double Hank ' s of equivalent liquid, and the packing small test tube, every pipe 0.5ml, then add 10%(S in pipe
AThe buffer solution preparation) hematocrit SRBC50 μ l, each 20 μ l of splenocyte suspension do two Duplicate Samples, rapidly after mixing, be poured on agarose thin layer slide, after agar solidifies, the slide level is buckled be placed on horse, put into CO2gas incubator and hatch 1.5h, then complement is joined in slide frame groove, continue incubation 1.5h, counting hemolysis plaque number.
2.2.6 serum hemolysin is measured (Hemagglutination Method): in gavage continuously after 30 days, every mouse peritoneal injection 2%SRBC0.2ml immunity, continue gavage after 5 days, extract eyeball and get blood in centrifuge tube, place 1h, peel off, the centrifugal 10min of 2000r/min collects serum, with physiological saline, serum is made doubling dilution, every part is diluted 12 holes, the dilution serum of difference is placed in blood-coagulation-board, every hole 100 μ l, add again 0.5%SRBC suspension 100 μ l, mixing is put observed result after wet 37 ℃ of 3h of box, records the aggegation degree in every hole.The calculating antibody product.
2.2.7NK cytoactive detection (lactate dehydrogenase L DH determination method): gavage is after 30 days continuously, and animal is put to death in the cervical vertebra dislocation, takes out spleen, tears up, and after crossing 200 eye mesh screens, uses Hank ' s liquid to wash 3 times, is made into 2 * 10 with complete RPMI1640 nutrient solution
7Individual/ml cell suspension.The cell suspension of each mouse is got 300 μ l divide 3 holes to be placed in 96 well culture plates, every hole 100 μ l, every hole adds target cell (YAC-1 cell, 4 * 10
5Individual/ml) 100 μ l do target cell Spontaneous release hole (target cell 100 μ l+ nutrient solution 100 μ l) and maximum release aperture (target cell 100 μ l+2.5%Triton100 μ l) each 8 holes, 37 ℃ of 5%CO simultaneously
2Cultivated 4 hours, and took out the centrifugal 5min of 1500r/min.Each hole supernatant 100 μ l are placed in another culture plate, and every hole adds 100 μ l matrix liquid again, adds the HCL30 μ l cessation reaction of 1mol/L after 10 minutes, in the 490nm mensuration OD of place value, calculates NK cytoactive rate.
3. test data is added up
Test data adopts the SPSS10.0forWindows software kit to process.The data of control group and dosage group are through the variance test of homogeneity, and variance is neat, carry out variance analysis,, compare in twos with the Dunnett method less than 0.05 as the P value; If heterogeneity of variance carries out data transaction, and is still uneven, use rank test instead, less than 0.05, use Dunnett ' sT3 method to compare in twos (P〉0.05 for non-significant difference, P＜0.05 is significant difference) as the P value.
4. result
4.1 the present invention sees Table 9-12 to the impact of Mouse Weight.
Table 9 is respectively organized the initial body weight of mouse
Table 10 is respectively organized the body weight in mid-term of mouse
Table 11 is respectively organized the end body weight of mouse
The impact of table 12 the present invention on the Mouse Weight weightening finish
By table 9-12 as seen, the initial body weight of one group, immune two groups of the present invention immunity, immune three groups and immune four groups of mouse is compared with negative control group, through the variance test of homogeneity, variance neat (P〉0.05), and the results of analysis of variance (P〉0.05) illustrates that respectively organizing mouse is balanced with initial body weight between negative control group.Three dosage group mouse test mid-terms, the body weight in latter stage and the growths of duration of test Mouse Weight are compared with negative control group, learn by statistics and process, there was no significant difference (P〉0.05), i.e. the present invention on the body weight gain of mouse without impact.
4.2 the impact of the present invention on mouse monokaryon-macrophage phagocytic function
Table 13 the present invention cleans up the impact of function to mouse monokaryon-macrophage carbon
By as seen from Table 13, gavage is after 30 days continuously, and the carbon of three dosage group mouse is cleaned up ability and compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05).
Table 14 the present invention engulfs the impact of chicken red blood cell ability on mouse macrophage
By as seen from Table 14, gavage is after 30 days continuously, and the phagocytic rate of three dosage treated animals is compared with negative control group with phagocytic index, learns by statistics and processes, and middle and high dosage group phagocytic index has significant difference (P＜0.05).
By table 13, as seen from Table 14, the present invention is positive to mouse monokaryon-macrophage phagocytic function test result.4.3 the impact of the present invention on the mouse cell immunity
The impact of table 15 the present invention on mouse delayed allergy (DTH)
By as seen from Table 15, gavage is after 30 days continuously, and the swelling degree of the paw of three dosage group mouse is compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05)
The impact of the mouse lymphocyte conversion test that table 16 the present invention induces ConA
By as seen from Table 16, the gavage mouse is after 30 days continuously, and the lymphopoiesis ability of three dosage group mouse is compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).
By table 15, the present invention is negative to mouse cell immunity test result as seen from Table 16.
4.4 the impact of the present invention on mouse humoral immune
The impact of table 17 the present invention on the mouse antibodies cellulation
By as seen from Table 17, gavage is after 30 days continuously, and the hemolysis plaque number of three dosage group mouse is compared with negative control, learns by statistics and processes, and low, middle dosage group has significant difference (P＜0.05).
The impact of table 18 the present invention on the mice serum hemolysin
By as seen from Table 18, gavage is after 30 days continuously, and the antibody product of three dosage group mouse is compared with negative control group, learns by statistics and processes, and low dose group has utmost point significant difference (P＜0.05)
By table 17, as seen from Table 18, the present invention is positive to the mouse humoral immune result of the test.
4.5 the impact of the present invention on the NK cells in mice activity
The impact of table 19 the present invention on the NK cells in mice activity
By as seen from Table 19, gavage is after 30 days continuously, and three dosage group NK cells in mice activity are compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).The present invention is aobvious negative to the NK cytoactive result of the test of mouse.
5. sum up
The continuous gavage mouse of the present invention had no significant effect Mouse Weight after 30 days; Test for celluar immunity result to mouse is negative; NK test cell line result to mouse is negative; To the test for humoral immunity of mouse, the hemolysis plaque number of three dosage groups and negative control group compare, and low, middle dosage group difference all has conspicuousness (P＜0.05), and result of the test is positive; To the monocytes/macrophages phagocytic function test of mouse, the phagocytic rate of three dosage group mouse and phagocytic index and negative control group compare, and middle and high dosage group difference has conspicuousness (P＜0.05), and result of the test is positive.
Can judge according to " health food check and assessment technique standard " version in 2003, the present invention has the function that strengthens immunity to animal.
Claims (7)
1. a health food that has antifatigue, strengthens immunity, is characterized in that, comprises the component of following percentage by weight: 10～50% ginseng, 10～50% barrenwort, 10～30% rhodiola root and 5～15% agate coffee.
2. the health food that has antifatigue, strengthens immunity according to claim 1, is characterized in that, is comprised of the component of following percentage by weight: 33% ginseng, 33% barrenwort, 22% rhodiola root and 12% agate coffee.
3. the health food that has antifatigue, strengthens immunity according to claim 1, is characterized in that, comprises that also percentage by weight is 5～60% ginkgo, 5～50% pseudo-ginseng, 5～50% puncture vine and 5～30% the fruit of Chinese magnoliavine.
4. the health food that has antifatigue, strengthens immunity according to claim 4, it is characterized in that, formed by the component of following percentage by weight: 20% ginseng, 20% barrenwort, 10% rhodiola root, 10% agate coffee, 20% ginkgo, 10% pseudo-ginseng, 5% puncture vine and 5% the fruit of Chinese magnoliavine.
5. according to claim 1～4 arbitrary described health foods that have antifatigue, strengthen immunity, is characterized in that, ginseng is replaced by American Ginseng.
6. the arbitrary described method that has antifatigue, strengthens the health food of immunity of preparation claim 1～5, is characterized in that, comprises the following steps: measure each raw material by formula, sieve respectively, mixed 15～20 minutes, make capsule.
7. preparation according to claim 6 has the method for the health food of antifatigue, enhancing immunity, it is characterized in that, selects≤100 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310068468XA CN103169079A (en) | 2013-03-04 | 2013-03-04 | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310068468XA CN103169079A (en) | 2013-03-04 | 2013-03-04 | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103169079A true CN103169079A (en) | 2013-06-26 |
Family
ID=48629623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310068468XA Pending CN103169079A (en) | 2013-03-04 | 2013-03-04 | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103169079A (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536659A (en) * | 2013-10-24 | 2014-01-29 | 丁志强 | Traditional Chinese medicine for adjusting dysfunction of qi and blood as well as preparation method thereof |
| CN104013664A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Preparation containing maca |
| CN104013663A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Preparation for effectively relieving exercise induced fatigue |
| CN104027380A (en) * | 2014-06-20 | 2014-09-10 | 苏州法莫生物技术有限公司 | Preparation for effectively relieving exercise induced fatigue |
| CN104027382A (en) * | 2014-06-20 | 2014-09-10 | 苏州法莫生物技术有限公司 | Antifatigue preparation |
| CN104187724A (en) * | 2014-08-21 | 2014-12-10 | 安徽广印堂中药股份有限公司 | Pseudo-ginseng health product and preparation method thereof |
| CN104224885A (en) * | 2014-09-11 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicine composition for relieving physical fatigue |
| CN104248035A (en) * | 2014-02-14 | 2014-12-31 | 亳州市益寿轩药膳食品有限公司 | Men's Maca health care solid beverage formula and preparation method |
| CN105105120A (en) * | 2015-09-02 | 2015-12-02 | 上海悦萌环保科技有限公司 | Maca healthcare product |
| CN105434576A (en) * | 2015-11-27 | 2016-03-30 | 天津天狮生物发展有限公司 | Composition with male healthcare function and preparation method thereof |
| CN105519954A (en) * | 2014-09-30 | 2016-04-27 | 河南世健生物科技有限公司 | Health food for enhancing human body immunity and preparation method thereof |
| CN105558528A (en) * | 2014-10-11 | 2016-05-11 | 华中科技大学 | Anti-fatigue Maca extract and functional drink including same |
| CN105614847A (en) * | 2015-12-23 | 2016-06-01 | 太仓东浔生物科技有限公司 | Anti-fatigue lozenge and preparation method therefor |
| CN106039035A (en) * | 2016-08-05 | 2016-10-26 | 杨贵林 | Traditional Chinese medicine composition for fully boosting immunity of human body |
| CN106511614A (en) * | 2016-11-21 | 2017-03-22 | 北华大学 | Anti-fatigue health food and production method thereof |
| CN106722965A (en) * | 2017-01-12 | 2017-05-31 | 浙江格蕾斯生物科技有限公司 | A kind of health caring product prescription for fatigue-relieving |
| CN107006857A (en) * | 2017-04-18 | 2017-08-04 | 百瑞德（南京）生物科技有限公司 | A kind of health food for adjusting immunologic function and preparation method thereof |
| CN107242563A (en) * | 2017-04-18 | 2017-10-13 | 百瑞德（南京）生物科技有限公司 | A kind of fatigue resistant health food and preparation method thereof |
| CN108813629A (en) * | 2018-07-23 | 2018-11-16 | 陈玉佩 | The health care product of strengthen immunity |
| CN105686006B (en) * | 2016-02-02 | 2019-03-19 | 福建省水产研究所 | One seed oyster composite function food and preparation method thereof |
| CN110652006A (en) * | 2019-10-12 | 2020-01-07 | 神威药业集团有限公司 | Composition for relieving physical fatigue and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002078746A1 (en) * | 2001-03-30 | 2002-10-10 | Altaffer, Paulo | Novel chocolate composition as delivery system for nutrients and medications |
| CN101062080A (en) * | 2006-04-26 | 2007-10-31 | 成都地奥九泓制药厂 | Medicinal composition for relieving fatigue and preparing process thereof |
| CN101804156A (en) * | 2010-04-02 | 2010-08-18 | 山东大学威海分校 | Preparation process and antifatigue effect of compound rhodiola root extractive |
| CN102613555A (en) * | 2012-03-30 | 2012-08-01 | 石药集团中奇制药技术（石家庄）有限公司 | Maca powder and ginseng composition and preparation method thereof |
-
2013
- 2013-03-04 CN CN201310068468XA patent/CN103169079A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002078746A1 (en) * | 2001-03-30 | 2002-10-10 | Altaffer, Paulo | Novel chocolate composition as delivery system for nutrients and medications |
| CN101062080A (en) * | 2006-04-26 | 2007-10-31 | 成都地奥九泓制药厂 | Medicinal composition for relieving fatigue and preparing process thereof |
| CN101804156A (en) * | 2010-04-02 | 2010-08-18 | 山东大学威海分校 | Preparation process and antifatigue effect of compound rhodiola root extractive |
| CN102613555A (en) * | 2012-03-30 | 2012-08-01 | 石药集团中奇制药技术（石家庄）有限公司 | Maca powder and ginseng composition and preparation method thereof |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536659A (en) * | 2013-10-24 | 2014-01-29 | 丁志强 | Traditional Chinese medicine for adjusting dysfunction of qi and blood as well as preparation method thereof |
| CN104248035A (en) * | 2014-02-14 | 2014-12-31 | 亳州市益寿轩药膳食品有限公司 | Men's Maca health care solid beverage formula and preparation method |
| CN104013664A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Preparation containing maca |
| CN104013663A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Preparation for effectively relieving exercise induced fatigue |
| CN104027380A (en) * | 2014-06-20 | 2014-09-10 | 苏州法莫生物技术有限公司 | Preparation for effectively relieving exercise induced fatigue |
| CN104027382A (en) * | 2014-06-20 | 2014-09-10 | 苏州法莫生物技术有限公司 | Antifatigue preparation |
| CN104187724A (en) * | 2014-08-21 | 2014-12-10 | 安徽广印堂中药股份有限公司 | Pseudo-ginseng health product and preparation method thereof |
| CN104187724B (en) * | 2014-08-21 | 2016-05-25 | 安徽广印堂中药股份有限公司 | A kind of Radix Notoginseng health products and preparation method thereof |
| CN104224885A (en) * | 2014-09-11 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicine composition for relieving physical fatigue |
| CN105519954A (en) * | 2014-09-30 | 2016-04-27 | 河南世健生物科技有限公司 | Health food for enhancing human body immunity and preparation method thereof |
| CN105558528B (en) * | 2014-10-11 | 2018-09-07 | 华中科技大学 | A kind of antifatigue Maca extract and the drinks including the extract |
| CN105558528A (en) * | 2014-10-11 | 2016-05-11 | 华中科技大学 | Anti-fatigue Maca extract and functional drink including same |
| CN105105120A (en) * | 2015-09-02 | 2015-12-02 | 上海悦萌环保科技有限公司 | Maca healthcare product |
| CN105434576A (en) * | 2015-11-27 | 2016-03-30 | 天津天狮生物发展有限公司 | Composition with male healthcare function and preparation method thereof |
| CN105614847A (en) * | 2015-12-23 | 2016-06-01 | 太仓东浔生物科技有限公司 | Anti-fatigue lozenge and preparation method therefor |
| CN105686006B (en) * | 2016-02-02 | 2019-03-19 | 福建省水产研究所 | One seed oyster composite function food and preparation method thereof |
| CN106039035A (en) * | 2016-08-05 | 2016-10-26 | 杨贵林 | Traditional Chinese medicine composition for fully boosting immunity of human body |
| CN106511614A (en) * | 2016-11-21 | 2017-03-22 | 北华大学 | Anti-fatigue health food and production method thereof |
| CN106722965A (en) * | 2017-01-12 | 2017-05-31 | 浙江格蕾斯生物科技有限公司 | A kind of health caring product prescription for fatigue-relieving |
| CN107006857A (en) * | 2017-04-18 | 2017-08-04 | 百瑞德（南京）生物科技有限公司 | A kind of health food for adjusting immunologic function and preparation method thereof |
| CN107242563A (en) * | 2017-04-18 | 2017-10-13 | 百瑞德（南京）生物科技有限公司 | A kind of fatigue resistant health food and preparation method thereof |
| CN108813629A (en) * | 2018-07-23 | 2018-11-16 | 陈玉佩 | The health care product of strengthen immunity |
| CN110652006A (en) * | 2019-10-12 | 2020-01-07 | 神威药业集团有限公司 | Composition for relieving physical fatigue and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169079A (en) | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof | |
| CN102204678B (en) | Instant cubilose powder with efficacy of immunity enhancement and preparation method thereof | |
| CN105310075A (en) | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid | |
| CN103829234A (en) | Health food capable of improving immunity and reducing blood fat and preparation method thereof | |
| CN102960715A (en) | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof | |
| CN102871120A (en) | Heath-care food for improving human immunity and preparation method thereof | |
| CN101810657B (en) | American ginseng contained composition and American ginseng tea drink | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN108157575A (en) | A kind of pressed candy for alleviating visual fatigue and preparation method and application | |
| CN104667197A (en) | Composition for strengthening immunity and preparation method and application of composition | |
| CN102429150A (en) | Vitamin C chewable tablet for enhancing human immunity | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN102754833B (en) | Healthcare product with function of enhancing immunity and preparation method thereof | |
| CN102987203A (en) | Immunity-improving and blood fat-reducing health food and preparation method thereof | |
| CN103039977A (en) | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof | |
| CN103478703A (en) | Health food with fatigue resistance function and preparation method thereof | |
| CN102860510A (en) | Anti-fatigue anti-anoxia health food and preparation method thereof | |
| CN111467468A (en) | Concentrated nutrient solution containing ginseng, cordyceps militaris, ginger and wolfberry fruit and preparation method thereof | |
| CN102920847B (en) | Composition for strengthening immunity and preparation and application thereof | |
| CN104585778A (en) | Albumen powder for improving organism immunity and preparation method of albumen powder | |
| CN102860509A (en) | Anti-fatigue immunity-improving health food and preparation method thereof | |
| CN102860495B (en) | Anti-anoxia immunity-improving health food and preparation method thereof | |
| CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN101940317B (en) | Health food for improving immunity of human bodies and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130626 |